Essentialis doses first patient in prader-willi syndrome trial
US-based pharmaceutical firm Essentialis has dosed the first patient in clinical study PC025, designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in patients with obese Prader-Willi syndrome (PWS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Eating Disorders & Weight Management | Obesity | Pharmaceuticals | Prader-Willi Syndrome | Study